NSCLC线:RCT

Zhifang Mao1, Zhiyong Zhang2, Meijiao Song1

  • 1Department of Oncology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.

Frontiers in oncology
|December 5, 2025
PubMed
概括

在亚洲患者中,PD-1/PD-L1抑制剂加上化疗显著改善了亚洲患者的IIIb-IV期非小细胞肺癌的存活率. 虽然这种组合疗法有效,但会增加与免疫相关的不良事件,需要仔细监测.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K